PMC10134052_01
Left buttock area, on single-agent pembrolizumab. From left to right: (a) prior to start of pembrolizumab, (b) after 2 cycles, (c) after 3 cycles, and (d) after 4 cycles.
cro530154_f01.jpg
PMC10134052_01_cro530154_f01.jpg
F1
After just two cycles of treatment, she was noted to have an exceptional response (Fig. 1a, b), with h further significant reduction in tumor size with each subsequent chemotherapy cycle (Fig. 1c, d).
CT evaluation of uterine mass. From left to right: (a) prior to the start of pembrolizumab (13.1 x 7.5 x 14.8 cm), (b) after 12 cycles of pembrolizumab (4.7 x 2.4 x 2.4 cm).
cro530154_f02.jpg
PMC10134052_01_cro530154_f02.jpg
F2
As shown in Figure 2, the uterine mass decreased in size from 13.1 x 7.5 x 14.8 cm to 4.7 x 2.4 x 2.4 cm after 12 cycles of single-agent pembrolizumab.